20 Participants NeededMy employer runs this trial

Tacrolimus Eye Drops for Anterior Uveitis

(EYETAC Trial)

Recruiting at 3 trial locations
AM
Overseen ByAlice Meides, PhD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Novaliq GmbH
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.

Who Is on the Research Team?

SK

Sonja Kroesser, PhD

Principal Investigator

Novaliq GmbH

Are You a Good Fit for This Trial?

Inclusion Criteria

My symptoms started within the last 4 weeks.
Provide written informed consent
I am 18 years old or older.
See 1 more

Exclusion Criteria

Have a condition or be in a situation (e.g. language barrier, non-cooperative, history of substance abuse) which the Investigator considers that it may put the patient at significant risk, may confound the trial results, or may significantly interfere with the patient's participation in the trial
Have severe/serious ocular pathology in the study eye which may preclude study completion or interferes with trial assessment, in the judgement of the clinical Investigator
I have active inflammation in the back part of my eye.
See 4 more

What Are the Treatments Tested in This Trial?

Interventions

  • Tacrolimus Ophthalmic Solution

How Is the Trial Designed?

2

Treatment groups

Active Control

Group I: Tacrolimus ophthalmic solution (low dose)Active Control1 Intervention
Group II: Tacrolimus ophthalmic solution (high dose)Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Novaliq GmbH

Lead Sponsor

Trials
12
Recruited
2,300+